Kawakami Takayuki, Mitsuhata Hiromasa, Saitoh Jin, Takeuchi Haruhiko, Hasome Naoki, Hiruta Masahiro, Horikawa Yukari, Seo Norimasa
Department of Anesthesiology and Critical Care Medicine, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Tochigi 329-0498, Japan.
J Anesth. 2003;17(1):22-9. doi: 10.1007/s005400300004.
The present study was done to investigate the role of endothelin-1 (ET-1) in hypotension and bronchospasm provoked by anaphylaxis in rabbits in vivo.
Forty-five rabbits sensitized to horse serum were randomly allocated to five groups: Group 1 (n = 10) received 0.5 nmol x kg(-1) of ET-1; Group 2 (n = 10) received 0.5 nmol x kg(-1) of ET-1 and 200 nmol x kg(-1) of a selective ETA receptor antagonist, BQ 610, without anaphylaxis; Group 3 (n = 5) received 200nmol x kg(-1) of BQ 610 alone without anaphylaxis, Group 4 (n = 10) received normal saline alone before being antigen challenged to induce anaphylaxis; Group 5 (n = 10) received 200 nmol x kg(-1) of BQ 610 before antigen challenge.
Mean arterial pressure (MAP) values were significantly different between Groups 1 and 2. Heart rate (HR), central venous pressure (CVP), dynamic pulmonary compliance (C(dyn)), and pulmonary airway resistance (R(L)) did not differ significantly between Groups 1 and 2. MAP values were significantly decreased compared with baseline in both Groups 4 and 5; however, the values were not significantly different between two groups. CVP values were significantly different between Groups 4 and 5 only at the 15-min time point following antigen challenge. HR, R(L), and C(dyn) values were not significantly different between Groups 4 and 5, nor were the survival rates.
BQ 610 does not improve hypotension or survival rates in systemic aggregated anaphylactic rabbits in vivo, implying that circulating ET-1 may not play an important role in anaphylaxis, although direct proof of production of circulating ET-1 or activation of ETA receptors is lacking in this study.
本研究旨在探讨内皮素 -1(ET-1)在兔体内过敏性反应诱发的低血压和支气管痉挛中的作用。
将45只对马血清致敏的兔子随机分为五组:第1组(n = 10)给予0.5 nmol·kg⁻¹的ET-1;第2组(n = 10)给予0.5 nmol·kg⁻¹的ET-1和200 nmol·kg⁻¹的选择性ETA受体拮抗剂BQ 610,未发生过敏反应;第3组(n = 5)仅给予200 nmol·kg⁻¹的BQ 610,未发生过敏反应;第4组(n = 10)在抗原激发诱导过敏反应前仅给予生理盐水;第5组(n = 10)在抗原激发前给予200 nmol·kg⁻¹的BQ 610。
第1组和第2组之间平均动脉压(MAP)值有显著差异。第1组和第2组之间心率(HR)、中心静脉压(CVP)、动态肺顺应性(C(dyn))和肺气道阻力(R(L))无显著差异。第4组和第5组的MAP值与基线相比均显著降低;然而,两组之间的值无显著差异。仅在抗原激发后15分钟时间点,第4组和第5组的CVP值有显著差异。第4组和第5组之间的HR、R(L)和C(dyn)值无显著差异,生存率也无显著差异。
BQ 610不能改善兔体内全身性聚集性过敏反应的低血压或生存率,这意味着循环中的ET-1在过敏反应中可能不起重要作用,尽管本研究缺乏循环ET-1产生或ETA受体激活的直接证据。